

**2nd International Symposium on
TRIGLYCERIDES AND HDL:
ROLE IN CARDIOVASCULAR DISEASE AND
THE METABOLIC SYNDROME**



POSTER SESSIONS

NOTE: THE AUTHOR LISTED IN BOLD TYPE IS THE PRESENTING AUTHOR.

Posters will be on display for the duration of the Symposium.

One author per poster will be available for discussion at the poster site during these times:

<i>Poster Viewing and Discussions</i>	<i>Thursday, July 14</i>	<i>4:30 p.m. – 6:30 p.m.</i>
<i>Poster Discussions and Reception</i>	<i>Friday, July 15</i>	<i>6:30 p.m. – 8:00 p.m.</i>
<i>Poster Viewing and Discussions</i>	<i>Saturday, July 16</i>	<i>11:00 p.m. – 12:30 p.m.</i>

*The Young Investigator Awards will be announced and presented during the
Poster Discussions and Reception on Friday, July 15 from 6:30 p.m. to 8:00 p.m.*

Poster Session 1

MOLECULAR MECHANISMS AND CLINICAL CONSEQUENCES OF INSULIN RESISTANCE, OBESITY AND METABOLIC SYNDROME

Poster No:		Abstract Book Page Reference
1.	CAROTID INTIMA-MEDIA THICKNESS IN A GENERAL POPULATION: ASSOCIATION WITH AGE, SEX LIPIDS, HYPERTENSION, DIABETES, AND ATHEROSCLEROTIC DISEASE Adolphe A.B. (Albuquerque, NM, USA)	33
2.	PLASMA TRIGLYCERIDES AND ECG ISCHEMIC DEPRESSION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS Aleksandrov A.A. , Kukhareno S.S., Bondarenko I.Z., Yadrinchinskaya M.N., Dedov I.I. (Moscow, Russia)	33
3.	TRIGLYCERIDES, HDL PLASMA LEVELS AND ADIPOSE TISSUE PARAMETERS IN MILD ARTERIAL HYPERTENSION Aleksandrov A.A. , Kukhareno S.S., Martyanova I.I., Popov Y.M., Olferiev A.M., Oganov R.G., Dedov I.I. (Moscow, Russia)	33
4.	HORMONAL PATTERNS OF DYSLIPIDAEMIAS IN NON-OBESE TYPE II DIABETIC PATIENTS WITH ATHEROSCLEROSIS Anestiadi V. , Anestiadi Z. (Chisinau, Moldova)	34
5.	HTS ASSAY DEVELOPMENT FOR CARDIOVASCULAR-RELEVANT LIPASES Bellanti B. , Arioli P., Redaelli L., Carettoni D. (Milan, Italy)	34
6.	HTS ASSAY DEVELOPMENT ON AN ACAT2 MUTANT WITH ENHANCED ENZYMATIC ACTIVITY Redaelli L., Arioli P., Iuzzolino L., Bellanti B. , Carettoni D. (Milan, Italy)	34
7.	LIPIDIC METABOLICAL DISORDER IN OBESE CHILDREN Boeriu E. , Cucuruz M., Marc M., Arghirescu S., Jinca C., Serban M. (Timisoara, Romania)	34
8.	SERUM LIPOPROTEINS IN CHILDREN WITH FAMILIAL HISTORY OF MYOCARDIAL INFARCTION Boeriu E. , Mancas S., Cucuruz M., Marc M., Arghirescu S., Jinca C., Serban M. (Timisoara, Romania)	35

Poster No:		Abstract Book Page Reference
9.	HYPOTRIGLYCERIDEMIA, INSULIN RESISTANCE AND LIVER DYSFUNCTION IN FAMILIAL HYPOBETALIPOPROTEINEMIA Hooper A.J., Robertson K., Barrett P.H.R., van Bockxmeer F.M., Burnett J.R. (Perth, Australia)	35
10.	COMPARISON OF LIPID & LIPOPROTEIN ASSESSMENT METHODS RELATED TO THE METABOLIC SYNDROME Davy B.M. , Alvarez G.E., Davy K.P. (Blacksburg, VA and San Antonio, TX, USA)	35
11.	PARTICULARITIES OF ADIPOSE TISSUE DISTRIBUTION IN PATIENTS WITH PRIMARY DIABETES MELLITUS TYPE 2 AND INSULIN RESISTANCE SYNDROME Davydov A.L. , Shchukina V.N., Shchavelev S.S. (Moscow, Russia)	35
12.	ELEVATED TRIGLYCERIDE LEVELS, MARKERS / RISK FACTORS FOR CARDIOVASCULAR DISEASE Deo S.S. , Mahadik S.R., Mokal R.A., Mithbawkar S.M., Thakur K. (Mumbai, India)	36
13.	METABOLIC SYNDROME PATIENTS WITH CABG AND ITS VASCULAR CONSEQUENCES Mancas S.G., Ionescu V.A. , Sarau C.A. (Timisoara, Romania)	36
14.	ELECTROPHYSIOLOGICAL PARAMETERS OF THE HEART IN PATIENTS WITH THE METABOLIC SYNDROME AND PAROXYSMAL ATRIAL FIBRILLATION Kipshidze N.N., Katsitadze G.A., Tedeev A.A., Khosroshvili L.B. (Tbilisi, Georgia)	36
15.	SICK SINUS NODE SYNDROME IN PATIENTS WITH METABOLIC SYNDROME Khosroshvili L.B. , Kipshidze N.N., Katsitadze G.A., Tedeev A.A. (Tbilisi, Georgia)	36
16.	LIPOPROTEIN PROFILE, CAROTID WALL THICKNESS AND IMPAIRED ENDOTHELIUM-DEPENDENT VASODILATATION IN SUBCLINICAL HYPOTHYROIDISM Kurtanidze T. , Tsiskarishvili D., Kakauridze N. (Tbilisi, Georgia)	37

17. SIX MONTH INCIDENCE OF CONFIRMED DIABETES AMONG 200 TREATED SCHIZOPHRENIA PATIENTS ENROLLED IN A PROSPECTIVE COHORT IN BELGIUM
L'Italien G.J., De Hert M., Thys E., Van Eyck D., Peuskens H., Wampers M., de Patoul A., Hanssens L., Scheen A. (Wallingford, CT, USA, Kortenbergh and Liege, Belgium) 37
18. THE POOLED PREVALENCE OF METABOLIC SYNDROME AMONG PATIENTS WITH SCHIZOPHRENIA
L'Italien G.J., Meyer J., Koro C.E. (Wallingford, CT, San Diego, CA, Collegeville, PA and Baltimore, MD, USA) 37
19. INTERACTION OF ZN⁺²-IONS WITH NOT DIABETOGENIC CHELATORS PROTECT B-CELLS OF DESTRUCTION CAUSED BY XANTURENIC ACID, A DIABETOGENIC METABOLITE OF TRYPTOPHAN
Meyramova A.G., Kikimbaeva A.A., Meyramov G.G. (Karaganda, Kazakhstan) 37
20. ASSOCIATION OF THE METABOLIC SYNDROME AND PROFILE OF INFLAMMATORY CYTOKINES IN LADA DIABETES
Nikonova T.V., Smirnova O.M., Dedov I.I. (Moscow, Russia) 38
21. CORRELATION OF HIGH-SENSITIVITY C-REACTIVE PROTEIN, FIBRINOGEN AND ULTRASONIC INDEX OF CAROTID ARTERIOSCLEROSIS IN PATIENTS WITH ACUTE CEREBRAL INFARCTION
Peng R., Liang Y., Zhou L., Wu Y., Zhao S., Yao H., Zhu Y. (Guangzhou, China) 38
22. THE METABOLIC SYNDROME, INSULIN RESISTANCE, AND CARDIOVASCULAR RISK IN DIABETIC AND NONDIABETIC PATIENTS
Saely C.H., Aczel S., Marte T., Langer P., Hoefle G., Drexel H. (Feldkirch, Austria) 38
23. PREVALENCE OF METABOLIC SYNDROME AMONG PATIENTS WITH ANGIOGRAPHICALLY-DOCUMENTED CORONARY ARTERY DISEASE
Santos R.S., Punzalan F.E.R., Sy R.S. (Pasig City, Philippines) 38

Poster No:		Abstract Book Page Reference
24.	OBESITY AND THE METABOLIC SYNDROME ARE ASSOCIATED WITH PARTIAL ANDROGEN DEFICIENCY IN AGING MEN Shah A.K. , Meehan A.G. (Rahway, NJ, USA)	39
25.	LIPID DISORDERS IN OBESE WOMEN Stojic D. , Novkovic M., Stojic J., Vejnovic M. (Sombor and Vrbas, Serbia)	39
26.	PLASMA PROCARBOXYPEPTIDASE U: A NOVEL COMPONENT OF THE METABOLIC SYNDROME Turkia B. , Silveira A., Shatteman K., Boquist S., Sharpe S., Hendriks D., Hamsten A. (Tbilisi, Georgia, Stockholm, Sweden and Antwerp, Belgium)	39
27.	TWO NOVEL APOA5 MISSENSE MUTATIONS IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEAMIA Zeng W.-W. , Whittall R., Schaap F.G., Putt W., Nierman M., Kuivenhoven J.A., Kastelein J., Hubacek J.A., Vrablik M., Humphries S.E., Talmud P.J. (Beijing, China, London, UK, Amsterdam, The Netherlands and Prague, Czech Republic)	39

Poster Session 2

MANAGEMENT OF INSULIN RESISTANCE, TYPE II DIABETES AND METABOLIC SYNDROME

Poster No:		Abstract Book Page Reference
28.	REDUCTION OF TIA BY ADDING NIACIN TO STATIN TREATED METABOLIC SYNDROME PATIENTS Dabhi A. , Dabhi L. (Ahmedabad, India)	40
29.	EFFECTS OF ROSUVASTATIN ON INSULIN SENSITIVITY IN PATIENTS WITH FAMILIAL COMBINED HYPERLIPIDEMIA de Graaf J. , ter Avest E., Abbink E.J., Tack C.J., Stalenhoef A.F.H. (Nijmegen, The Netherlands)	40
30.	GOINO PROCEDURE AS POSSIBLE PROPHYLACTIC AGENT AGAINST CARDIAC DISORDERS ASSOCIATED WITH NON INSULIN DEPENDENT DIABETES MELLITUS Goino T. , Kitamura T. (Nagano, Japan)	40
31.	EFFECT OF CAPTOPRIL ON METABOLIC SYNDROME IN FRUCTOSE-INDUCED FATTY LIVER DISEASE Grozovski M. , Oron-Herman M., Rosenthal T., Pappo O., Link G., Sela B.-A. , Ackerman Z. (Karmiel, Tel Aviv, Tel Hashomer and Jerusalem, Israel)	40
32.	DIET INDUCED CHANGES IN BLOOD LIPID AND INFLAMMATORY MARKERS Gundry S.R. , Ehrman W.L. (Palm Springs, CA, USA)	41
33.	GENDER AND AGE RELATED DIFFERENCES IN TREATMENT AND CONTROL OF CARDIOVASCULAR RISK FACTORS IN HYPERTENSIVE PATIENTS WITH ANGINA Hendrix K.H. , Mayhan S., Egan B.M. (Charleston, SC, USA)	41
34.	THE EFFECTS OF PHASE II OF CARDIOVASCULAR REHABILITATION ON LIPIDS AND LIPOPROTEINS IN DIABETIC PATIENTS WITH AND WITHOUT SYMPTOMATIC CORONARY ARTERY DISEASE Mancas S.G., Ionescu V.A. , Sarau C.A. (Timisoara, Romania)	41

Poster No:		Abstract Book Page Reference
35.	<p>CHROMIUM PICOLINATE AND BIOTIN COMBINATION REDUCES ATHEROGENIC INDEX OF PLASMA IN PATIENTS WITH TYPE 2 DIABETES</p> <p>Juturu V., Geohas J., Finch M., Komorowski J.R. (Purchase, NY and Chicago, IL, USA)</p>	41
36.	<p>STATIN AND ANTIHYPERTENSIVE PREPARATIONS COMBINE THERAPY FOR THE PATIENTS WITH METABOLIC SYNDROME</p> <p>Levchenko T.P., Karachentsev Y.I., Snegurskaya I.A., Kravchun N.A., Miloslavskii D.K., Bojko V.V. (Kharkov, Ukraine)</p>	42
37.	<p>EFFECT OF EZETIMIBE/SIMVASTATIN ON THE LIPID PROFILE OF HYPERCHOLESTEROLEMIC PATIENTS WITH METABOLIC SYNDROME</p> <p>MacCubbin D., Ose L., Feldman T., Zakson-Aiken M., Shah A., Tribble D., Veltri E., Mitchel Y. (Rahway, NJ and Miami FL, USA and Oslo, Norway)</p>	42
38.	<p>THE ACHIEVEMENT OF BLOOD PRESSURE GOAL IN METABOLIC SYNDROME PATIENTS: THE ACE INHIBITOR EFFECTS ON LIPID METABOLISM AND INSULIN RESISTANCE</p> <p>Mamedov M.N., Serdyuk A.P. (Moscow, Russia)</p>	42
39.	<p>INFLUENCE OF MOXONIDINE ON INSULIN RESISTANCE AND LIPID LEVELS IN SUBJECTS WITH METABOLIC SYNDROME</p> <p>Kondratskaya I.N., Mankovsky B.N. (Kiev, Ukraine)</p>	42
40.	<p>INFLUENCE OF THE METABOLIC SYNDROME ON MEAN AGE OF ONSET OF CORONARY HEART DISEASE IN MAURITIUS</p> <p>Manraj M., Hébé A., Sem Fa N., Lee Kwai Yan S., Ramjutun U.S. (Reduit, Mauritius)</p>	43
41.	<p>MEDITERRANEAN DIET ENRICHED IN EITHER NUTS OR OLIVE OIL REDUCES PLASMA AND VLDL CHOLESTEROL AND TRIGLYCERIDES: THE PREDIMED STUDY</p> <p>Perona J.S., Fito M., Estruch R., Covas M.I., Corella D., García M., Cabezas C., Salas J., Ruiz-Gutierrez V., on behalf of the Grupo del Estudio PREDIMED (Seville, Barcelona and Valencia, Spain)</p>	43

Poster No:		Abstract Book Page Reference
42.	PHYSICAL EXERCISE CAN BENEFIT METABOLIC DISTURBANCES IN OBESE DIABETICS Pudar G. , Brankovic A. (Belgrade, Serbia and Montenegro)	43
43.	EFFECT OF ORLISTAT ON WEIGHT AND OTHER CARDIOVASCULAR RISK PROFILE IN OBESE PATIENTS: A META-ANALYSIS Santos R.S. , Punzalan F.E. (Pasig City, Philippines)	43
44.	ROLE OF LIFESTYLE MODIFICATIONS IN HYPERTENSIVE AND OBESE PATIENTS Santos R. , Freitas J., Macedo M.E., Rebelo I. (Pedrouços, Portugal)	44
45.	EFFECT OF ATORVASTATIN ON LIPID PROFILE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND METABOLIC SYNDROME Sulakvelidze M.G. , Kipshidze N.N. (Tbilisi, Georgia)	44
46.	PREVALENCE OF THE METABOLIC SYNDROME IN YOUNG ADULT FILIPINOS AGED 18 - 25 YEARS OLD: A PRELIMINARY REPORT Sy R.G. , Punzalan J., Soria M., Dimaano J., Cespedes M., Encabo R., Lazam B. (Manila, Philippines)	44
47.	PREVALENCE OF METABOLIC SYNDROME IN A SAMPLE OF HYPERTENSIVE PATIENTS TREATED IN PRIMARY CARE Vicente-Casanova A. , Lozano J.V., Aznar J., Fernández-Guardiola E. (Valencia, Denia-Alicante and Barcelona, Spain)	44
48.	DIFFERENT LISTS OF RECOMMENDED INDO-MEDITERRANEAN FOODS TO TREAT DIFFERENT FEATURES OF METABOLIC SYNDROME (MetS) Volpe R. , Pille J., Prakash S., Nantel G. (Rome, Italy)	45
49.	A 12-WEEK VERY-LOW CARBOHYDRATE DIET (VLCD) SIGNIFICANTLY REDUCES CASES OF THE METABOLIC SYNDROME IN MEN Wood R.J. , Volek J.S., Fernandez M.L. (Storrs, CT, USA)	45

Poster Session 3

TRIGLYCERIDE-RICH LIPOPROTEINS, INFLAMMATION AND
ATHEROSCLEROSIS

Poster No:		Abstract Book Page Reference
50.	THE MULTIDOMAIN ORGANIZATION AND THE STABILITY OF HUMAN APOLIPOPROTEIN E2, E3 AND E4 IN SOLUTION Dergunov A.D. , Barbier A., Clément-Collin V., Visvikis A., Siest G., Desmadril M., Takahashi M., Aggerbeck L.P. (Moscow, Russia, and Nancy, Gif-sur-Yvette and Orsay, France)	45
51.	THE SIGNIFICANCE OF APOE PHENOTYPE TO THE COMPOSITION, STRUCTURE AND BINDING OF VLDL AND LDL TO THE LDL RECEPTOR IN NORMO- AND HYPERTRIGLYCERIDEMIA Dergunov A.D. , Novoselov A.V., Smirnova E.A., Visvikis S., Siest G. (Moscow, Russia and Nancy, France)	45
52.	THE TERTIARY AND QUATERNARY STRUCTURE OF HUMAN APOLIPOPROTEIN E2, E3 AND E4 IN SOLUTION Dergunov A.D. , Barbier A., Clément-Collin V., Visvikis A., Siest G., Aggerbeck L.P. (Moscow, Russia and Nancy and Gif-sur-Yvette, France)	46
53.	HETEROZYGOUS MUTATION OF ATAXIA TELANGIECTASIA MUTATED GENE AGGRAVATES HYPERCHOLESTEROLEMIA IN APOE-DEFICIENT MICE Yang H., Wu D.F., Zhou L.C., Ballard B.R., Guo Z.M. (Nashville, TN, USA)	46
54.	THE EFFECTS OF HYPERBARIC OXYGEN TREATMENT ON THE REGRESSION OF ATHEROSCLEROSIS IN RABBITS Jovanovic T. , Brkic P., Mitrovic A. (Belgrade, Serbia and Montenegro)	46
55.	TRIGLYCERIDES TO HIGH DENSITY LIPOPROTEIN CHOLESTEROL RATIO AS A PREDICTOR OF C-REACTIVE PROTEIN IN MILITARY PILOTS IN THE SERBIA AND MONTENEGRO Jovelic A. , Markovic M., Radjen G., Rudnjanin S. (Belgrade, Serbia and Montenegro)	46

Poster No:		Abstract Book Page Reference
56.	<p>HYPERTRIGLYCERIDEMIA IS ASSOCIATED WITH IMPAIRED ENDOTHELIUM-DEPENDENT VASODILATION AND MARKERS OF OXIDATIVE STRESS Kraml P.J., Fialová L., Syrovátka P., Anděl M. (Prague, Czech Republic)</p>	47
57.	<p>DECREASED LIPOPROTEIN LIPASE ACTIVITY (LPL) AND INCREASED CONCENTRATIONS OF POSTPRANDIAL TRIGLYCERIDE-RICH LIPOPROTEINS (TRL) IN ELDERLY SURVIVORS OF MYOCARDIAL INFARCTION Lekhal S., Boervik T., Nordoy A., Hansen J.B. (Tromsø, Norway)</p>	47
58.	<p>TRIGLYCERIDES, HDL CHOLESTEROL AND ACCUMULATION OF RISK FACTORS IN A PORTUGUESE SAMPLE POPULATION Lima Faleiro L., Martins M.C., Fonseca A.E. (Lisbon, Portugal)</p>	47
59.	<p>GENDER AND AGE RELATED DIFFERENCES IN TREATMENT AND CONTROL OF CARDIOVASCULAR RISK FACTORS AMONG HIGH-RISK PATIENTS WITH ANGINA Hendrix K.H., Mayhan S., Egan B.M. (Charleston, SC and Palo Alto, CA, USA)</p>	47
60.	<p>INTERMEDIATE DENSITY LIPOPROTEIN STIMULATES ALTERED EXPRESSION AND DISTRIBUTION OF VCAM-1 McFarlane C., Young I.S., Frizzell N., McKibben B., McEneny J. (Belfast, UK)</p>	48
61.	<p>THE OXIDATION POTENTIAL OF VLDL, LDL AND HDL IN THE PRESENCE OF 5 DIFFERENT FLAVONOIDS Martin A., Young I.S., McKibben B., McEneny J. (Belfast, UK)</p>	48
62.	<p>HYPERLIPIDEMIC SERUM CAN INDUCE A NOVEL MARKER (PC-CHOLESTEROL COMPLEX) OF FOAM CELL DEATH Mori M., Ogasawara H., Tanaka A., Soshi R., Asano T., Kagiwada S., Isomura A., Itabe H., Takano T. (Kanagawa and Tokyo, Japan)</p>	48
63.	<p>HYPERHOMOCYSTEINEMIA IN CHRONIC HEART FAILURE Naruszewicz M., Zymliński R., Bukowska H., Millo B., Jankowska E.A., Banasiak W., Ponikowski P. (Szczecin and Wrocław, Poland)</p>	48

64. TRIGLYCERIDE RICH-LIPOPOTEINS FROM HYPERTRI-GLYCERIDEMIC SUBJECTS INDUCE A PRO-INFLAMMATORY PATTERN IN ENDOTHELIAL CELLS: MOLECULAR MECHANISMS AND GENE EXPRESSION STUDIES
Norata G.D., Eriksson P., Grigore L., Raselli S., Seccomandi P., Hamsten A., Maggi F.M., Catapano A.L. (Milan and Cinisello Balsamo, Italy and Stockholm, Sweden) 49
65. THE INTERACTION BETWEEN POSTPRANDIAL TRIGLYCERIDES, LIPOPROTEIN LIPASE (LPL) ACTIVITY AND APOLIPOPROTEIN C-I (APO C-I)
Notoe A.T.W., Mathiesen E.B., Bjorkegren J., Hansen J.B. (Tromsø, Norway and Stockholm, Sweden) 49
66. THE ROLE OF TG AND HDL LEVELS ON LATTER THROMBOTIC STROKE IN GREEK POPULATION
Paximadas S., Pagoni S., Nikitopoulou P., Garefalakis K., Katsigianni G., Pantelidis P. (Athens, Greece) 49
67. MINOR COMPONENTS OF VIRGIN OLIVE OIL AFFECT TRIGLYCERIDE-RICH LIPOPROTEIN HYDROLYSIS BUT NOT UPTAKE BY RAT HEPATOCYTES
Perona J.S., García M., Avella M., Botham K.M. , Ruiz-Gutierrez V. (Seville, Spain and London, UK) 49
68. IL-1 β AFFECTS LIPID METABOLISM IN MACROPHAGE-DERIVED FOAM CELLS
Persson J., Nilsson J., Lindholm M.W. (Malmö, Sweden) 50
69. ASSOCIATIONS BETWEEN DIFFERENT LEUCOCYTE COUNTS AND THE ACUTE MYOCARDIAL INFARCTION
Rosoklija A., Georgievska-Ismail L. (Tripoli, Libya and Skopje, Macedonia) 50
70. ADIPOPILIN INCREASES TRIGLYCERIDES STORAGE IN HUMAN MACROPHAGES POTENTIALLY THROUGH A REDUCTION OF FATTY ACIDS β -OXIDATION
Larigauderie G., Furman C., Lasselin C., Copin C., Jaye M., Fruchart J-C., **Rouis M.** (Lille, France and King of Prussia, PA, USA) 50

Poster No:

71. EVIDENCE FOR ELEVATED TRIGLYCERIDES AND LOW HDL
CHOLESTEROL AS THE MAIN LIPID RISK FACTORS FOR
DIABETIC ATHEROSCLEROSIS
Saely C.H., Aczel S., Marte T., Langer P., Moll W., Schmid F.,
Koch L., Drexel H. (Feldkirch, Austria) 50

Poster Session 4

TREATMENT OF DYSLIPIDEMIA

Poster No:		Abstract Book Page Reference
72.	EVALUATION OF <i>EZETIMIBE/SIMVASTATIN</i> VERSUS <i>ATORVASTATIN</i> ON ATHEROGENIC RATIOS OF NON-HDL-C/ HDL-C AND APO B/APO A-1 Ballantyne C.M. , Abate N., King T.R., Yuan Z., Palmisano J. (Houston and Dallas, TX and West Point, PA, USA)	51
73.	PLEIOTROPIC EFFECTS OF LONG-TERM <i>ATORVASTATIN</i> TREATMENT IN PATIENTS WITH CORONARY ARTERY DISEASE Chumburidze S. (Tbilisi, Georgia)	51
74.	SAFETY OF <i>ATORVASTATIN</i> IN ELDERLY PATIENT POPULATION Hey-Hadavi J.H. , Kuntze E., Luo D., Silverman P., Pittman D., Lepetri B. (New York, NY, USA)	51
75.	EVALUATION OF THE SAFETY AND THE LIPID LOWERING EFFECTS OF TWO WEEKS <i>ROSUVASTATIN</i> TREATMENT IN PATIENTS WITH CORONARY HEART DISEASE Kapanadze K. (Tbilisi, Georgia)	51
76.	BENEFICIAL EFFECTS OF <i>SIMVASTATIN</i> (VASILIP) THERAPY ON ENDOTHELIAL FUNCTION AND INFLAMMATORY MARKERS IN PATIENTS WITH CORONARY HEART DISEASE (CHD) Chapidze G., Tsiskarishvili D., Dolidze N., Rigvava L., Lomtadze G., Kapanadze S., Kurtanidze T. , Chagunava K. (Tbilisi, Georgia)	52
77.	EFFECTS OF ARTERODIET ON BLOOD HDL-C AND LEVEL OF NITRIC OXIDE IN PATIENTS WITH CORONARY HEART DISEASE Chapidze G., Kapanadze S., Dolidze N., Latsabidze N. (Tbilisi, Georgia)	52
78.	TREATMENT WITH COENZYME Q10 AND <i>SIMVASTATIN</i> IN PATIENTS FOLLOWING MYOCARDIAL REVASCULARIZATION Chapidze G., Kapanadze S., Dolidze N., Latsabidze N. (Tbilisi, Georgia)	52

Poster No:		Abstract Book Page Reference
79.	EFFECTS OF DIETARY PHYTIC ACID ON THE SERUM LIPID LEVELS IN AGED MICE Chun H.-K., Lee S.-H. , Cho S.-Y., Chung H.-J., Park H.-J., Cho S.-M., Lee Y.-M., Lillehoj H.-S. (Beltsville, MD, USA and Suwon, Korea)	52
80.	A NEW GENERATION OF ACTIVE COMPOUNDS FOR DYSLIPIDEMIA LOWERING BOTH CHOLESTEROL AND TRIGLYCERIDES - NUTRISEQUENCE TC Lugand Bourgeois M. , Cornély A. (Monthey, Switzerland)	53
81.	THE EFFECT OF STATIN THERAPY AT RECURRENT CORONARY EVENTS IN PATIENTS FOLLOWING CORONARY STENT IMPLANTATION Miloradovic V. , Jovanovic M., Miloradovic M. (Kragujevac, Serbia and Montenegro)	53
82.	ATORVASTATIN AND ITS EFFECTS ON VCAM-1, ICAM-1 AND ENDOGLIN ENDOTHELIAL EXPRESSION IN APOE-KNOCKOUT MICE Nachtigal P. , Pospíšilova N., Pospěchová K., Jamborová G., Solichová D., Ždánský P., Semecký V. (Hradec Kralove, Czech Republic)	53
83.	STATINS INFLUENCE ON THE DYNAMICS OF HDL-C AND TG LEVEL IN HELICOBACTERY PYLORI AND CHLAMIDIA PNEUMONIAE INFECTED CHD PATIENTS Kipshidze N., Nikolaishvili G. , Kakauridze N. (Tbilisi, Georgia)	53
84.	AN ANALYSIS OF C-REACTIVE PROTEIN AND THE EFFICACY OF EZETIMIBE ADDED TO STATIN THERAPY Pearson T., Denke M., McBride P., Gazzara R.A., Brady W.E., Palmisano J. (Rochester, NY, Kerrville, TX, Madison, WI and West Point, PA, USA)	54
85.	EZETIMIBE ADDED TO STATIN THERAPY REDUCES LDL-C, TG AND NON-HDL-C AND IMPROVES HDL-C IN PATIENTS WITH DIABETES AND METABOLIC SYNDROME Denke M., McBride P., Pearson T., Gazzara R.A., Brady W.E., Palmisano J. (Kerrville, TX, Madison, WI, Rochester, NY and West Point, PA, USA)	54

Poster No:		Abstract Book Page Reference
86.	ACTIVATION OF OVEREXPRESSED PPAR γ INDUCED FOAM CELL LIKE CHANGES IN RAT VSMC Park H.Y. , Lim H.J., Lee K.S., Lee S., Park J.H. (Seoul, South Korea)	54
87.	“60 - 60 - 60” ENGINEERING NEGLIGIBLE VASCULAR SENESCENCE FROM A PARTICLE-GRADIENT DRIVEN PERSPECTIVE Tapp J.C. (Bowling Green, KY, USA)	54
88.	EFFECTS OF FENOFIBRATE AND EZETIMIBE ON LIPOPROTEIN SUBCLASSES AND LDL SIZE PATTERN IN PATIENTS WITH MIXED HYPERLIPIDEMIA Tribble D. , Farnier M., Mitchel Y., Gumbiner B. (Rahway, NJ, USA and Dijon, France)	55
89.	TEN YEARS OF PRAVASTATIN (P) PLUS FENOFIBRATE (F) THERAPY IN PATIENTS WITH FAMILIAL COMBINED HYPERLIPIDEMIA (FCH) Volpe R. , Rossetti A., Mazzarella B., Pacioni F., Valle S. (Rome, Italy)	55
90.	THE EFFECTS OF THE CURCUMIN ON THE LOWERING-LIPIDS, ANTIOXIDATION AND ANTIATHEROSCLEROSIS Wo X. , Hong X., Tang L., Gao C. (Hangzhou, China)	55

Poster Session 5

PHYSIOLOGY, PATHOLOGY AND PHARMACOLOGY OF HDL

Poster No:		Abstract Book Page Reference
91.	CONNECTION BETWEEN ATHEROMATIC CORONARY DISEASE AND LIVER STEATOSIS Agapitos E. , Theoharis S., Kanderakis S., Anastasakis A., Koutsaftis F., Patsouris E. (Piraeus and Athens, Greece)	55
92.	EFFECTS OF ATORVASTATIN ON HDL-APO A-I KINETICS IN DOG Briand F. , Nguyen P., Krempf M., Magot T., Ouguerram K. (Nantes, France)	56
93.	INFLAMMATION INCREASES HDL BINDING TO PROTEOGLYCANS Chiba T. , Han C.Y., Heinecke J., Oram J.F., Chait A. (Seattle, WA, USA)	56
94.	NEW INSIGHTS INTO HDL-INDEPENDENT CHOLESTEROL EFFLUX FROM HUMAN MONOCYTE-DERIVED MACROPHAGES Cignarella A. , Engel T., von Eckardstein A., Cullen P., Assmann G. (Milan and Padua, Italy, Münster, Germany and Zurich, Switzerland)	56
95.	ELEVATED HDL DETERMINES RISK OF RECURRENT CORONARY EVENTS WITHIN A HIGH-RISK SUBGROUP OF NON-DIABETIC POSTINFARCTION PATIENTS WITH HYPERCHOLESTEROLEMIA AND INFLAMMATION Corsetti J.P. , Zareba W., Moss A.J., Rainwater D., Sparks C.E. (Rochester, NY and San Antonio, TX, USA)	56
96.	RAISING HDL IIB WITH DIET AND SUPPLEMENTS: ACCOMPLISHING THE IMPOSSIBLE? Gundry S.R. , Ehrman W.L. (Palm Springs and Loma Linda, CA, USA)	57
97.	PROBUCOL STABILIZES HEPATIC SCAVENGER RECEPTOR CLASS B TYPE I POSSIBLY THROUGH SPECIES-SPECIFIC FASHION Hirano K. , Ikegami C., Tsuji K., Koseki M., Masuda D., Nakagawa-Toyama Y., Ueda Y., Shimomura I., Yamashita S. (Osaka and Shiga, Japan)	57

Poster No:		Abstract Book Page Reference
98.	DIABETIC WOMEN HDL CHOLESTEROL BEHAVIOUR AND EXERCISE TRAINING INDIVIDUALIZATION IN SECONDARY PREVENTION OF CORONARY ARTERY DISEASE Ionescu V.A. , Mancas S.G., Duda-Seiman D.M. (Timisoara City, Romania)	57
99.	OXIDISED HDL SUBFRACTIONS ALTERS THE RELEASE OF PRO-INFLAMMATORY CYTOKINES FROM HUVECs McPherson P. , Donnelly K., Young I., Connelly R., McGinty A., McEneny J. (Belfast, UK)	57
100.	IMPORTANCE OF HDL-C ON CARDIOVASCULAR PREVENTION. RECOMMENDATIONS OF HDL-FORUM IN SPAIN Millan J. , Ascaso J., Fernandez-Cruz A., Gonzalez Santos P., Hernandez Mijares A., Mangas A., Pallardo L.F., Pedro-Botet J.C., Perez Jimenez F., Pia G., Pintó X., Plaza I., Rubiés J., Querol M., Ros C., on behalf of HDL-Forum of Spain (Madrid, Spain)	58
101.	HDL-CHOLESTEROL IS HIGHER IN WOMEN THAN IN MEN WITH ACUTE CORONARY SYNDROME WITHOUT ST-ELEVATION Sinkovic A. , Pogacar V., Marinsek M. (Maribor, Republic of Slovenia)	58